PA1010

DRUG2 trials

Sponsors

Zhejiang Palo Alto Pharmaceuticals, Inc.

Conditions

Chronic HBV Infection

Phase 1

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

CompletedNCT05019040

Zhejiang Palo Alto Pharmaceuticals, Inc.Chronic HBV Infection

Start: 2021-09-17End: 2022-11-18Updated: 2023-01-31

Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

CompletedNCT05468060

Zhejiang Palo Alto Pharmaceuticals, Inc.Chronic HBV Infection

Start: 2020-06-28End: 2020-12-12Updated: 2022-07-21